MIAMISBURG, Ohio--(BUSINESS WIRE)-- Aerobiotix today announced a strategic partnership with the Association for Professionals in Infection Control and Epidemiology (APIC), the largest association for infection prevention and control (IPC) professionals. Since 2018, Aerobiotix has been a Strategic Partner and has again signed on as a 2021 APIC Strategic Partner.

According to the Centers for Disease Control and Prevention, an estimated 633,000 hospitalized patients get healthcare associated infections (HAIs) each year and 72,000 die during their hospital stay. With the onset of the COVID-19 pandemic in 2020, the importance of providing state-of-the-art education and support services for professionals in infection prevention and control was further reinforced.

The APIC Strategic Partner program establishes long-term relationships with industry partners united in the common goal of reducing the risk of infection. APIC Strategic Partners play an important role in supporting many of the educational initiatives and services that benefit APIC’s almost 16,000 infection preventionist (IP) members fighting on the front-lines against the spread of harmful microorganisms and viruses, such as C. diff, MRSA, and SARS-CoV-2 in healthcare facilities.

“Aerobiotix is pleased to partner with APIC to help prevent the spread of infection and expand education and resources for IPs,” said Dr. Kirschman, CEO. “We share APIC’s patient safety mission and hope this partnership will help to strengthen APIC’s efforts to create a safer world through the prevention of infection.” Dr. Kirschman further states, “We look forward to bringing our educational opportunities to APIC’s members in airborne transmissions and their effect on infection rates.”

APIC Strategic Partners fully support the Competency Advancement Assistance (CAA) Program to help IPs further their education by managing the cost associated with obtaining the Certification in Infection Prevention and Control (CIC®) credential. The CAA program covers exam fees and study resources for up to 50 IPs annually.

“We are excited to welcome Aerobiotix as an APIC Strategic Partner,” said APIC CEO Devon Jopp. “Together, APIC and Aerobiotix will work together to improve healthcare outcomes and advance education and certification for IPC professionals.”

About Aerobiotix:

AEROBIOTIX® is a medical device company improving patient outcomes by transforming the physical environment of care. We utilize proprietary technologies to remove airborne microorganisms within acute environments and deliver measurable, data-driven, and peer-supported improvements to patient outcomes and staff safety. Visit us at www.aerobiotix.com.

First launched in 2017, the ILLUVIA® Air Disinfection System is a mobile air handling device which uses novel photolysis and mechanical filtration technologies to achieve air disinfection. It is intended to produce a directed, nonturbulent flow of air that has been treated to remove microorganisms to provide an area free of contaminants in critical healthcare settings, including surgical and procedural areas.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210120005558/en/